According to the study Gone Tomorrow? A Call to Promote Medical Innovation, Create Jobs, and Find Cures in America, the US is facing serious challenges when it comes to medical innovation. It will become difficult for America to maintain its position as the global leader in medical innovation. Continue reading
Roche has obtained a licence for a biomarker from Qiagen
Roche has linked up with Qiagen from the Netherlands to develop tests for a key cancer biomarker.
The large company from Switzerland has obtained a worldwide co-exclusive licence for the biomarker PI3K (phosphoinositide 3-kinase) from Qiagen to develop diagnostic assays. Continue reading
Posted in Deals & Acquisitions
Leave a comment
Sanofi-Aventis buys TargeGen for a total of $560 million
Sanofi-Aventis has this morning revealed it has agreed to purchase privately-held TargeGen Inc. to add treatments for certain forms of leukemia and blood disorders.
Sanofi will pay $75 million as an upfront-payment to TargeGen, which is developing small molecule kinase inhibitors for the treatment of certain forms of leukaemia, lymphoma and other haematological malignancies and blood disorders.
Posted in Deals & Acquisitions
1 Comment
A Gloomy Picture of the Global Pharmaceuticals Sector
Big Pharma still heavily relies on sales from an ageing portfolio of products and the proportion of sales from newer medicines actually fell last year, after a decade of record research spending yielded few new winners.
The 2010 Pharmaceutical R&D Factbook, compiled by CMR International and released on Monday, painted a gloomy picture of the global pharmaceuticals sector.
New drugs launched within the last five years accounted for less than 7 percent of industry sales in 2009, down from 8 percent in 2008, the Factbook showed, highlighting the big problems that companies are having in trying to reinvigorate their portfolios. Continue reading
Posted in Pharma
Leave a comment
Increasing Immune Response against Cancers and Infectious Diseases.
Inovio Pharmaceuticals is a company that focuses on developing a new generation of vaccines called DNA vaccines. These are to prevent and treat cancers, influenza and other challenging diseases caused by, for example, HIV and HPV.
Inovio, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled “IL-28B/IFN-lambda3 Drives Granzyme B Loading and Significantly Increases CTL Killing Activity in Macaques.”
With this study, they have shown that they are able, with their innovative DNA vaccine technology-platform, to increase immune responses to diseases in non-human primates. Continue reading
Posted in Innovations and business
Leave a comment